 | • レポートコード：GIR201107986 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、139ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、横紋筋肉腫治療薬の世界市場を調査対象にし、横紋筋肉腫治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（ARI-4175、セリビル、クリゾチニブ、エノブリツズマブ、AT-69、アキシチニブ、その他）、用途別分析（研究センター、病院、クリニック、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Bellicum Pharmaceuticals Inc、Iproteos SL、Celgene Corp、Boehringer Ingelheim GmbH、Exelixis Inc、Bristol-Myers Squibb Co、MacroGenics Inc、Epizyme Inc、Eisai Co Ltd、Ipsen SA、Taiho Pharmaceutical Co Ltd、NantKwest Inc、Taiwan Liposome Company Ltd、Pfizer Inc、Novartis AG、Tarveda Therapeutics Inc、Noxxon Pharma AG ・メーカー別販売量、売上、市場シェア ・横紋筋肉腫治療薬の地域別市場分析 ・横紋筋肉腫治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・横紋筋肉腫治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・横紋筋肉腫治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・横紋筋肉腫治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・横紋筋肉腫治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・横紋筋肉腫治療薬の種類別市場規模2015-2020：ARI-4175、セリビル、クリゾチニブ、エノブリツズマブ、AT-69、アキシチニブ、その他 ・横紋筋肉腫治療薬の用途別市場規模2015-2020：研究センター、病院、クリニック、その他 ・横紋筋肉腫治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Rhabdomyosarcoma Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Rhabdomyosarcoma Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Rhabdomyosarcoma Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Rhabdomyosarcoma Drug market has been segmented into
ARI-4175
Celyvir
Crizotinib
Enoblituzumab
AT-69
Axitinib
Others
By Application, Rhabdomyosarcoma Drug has been segmented into:
Research Center
Hospital
Clinic
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Rhabdomyosarcoma Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Rhabdomyosarcoma Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Rhabdomyosarcoma Drug market.
The report offers in-depth assessment of the growth and other aspects of the Rhabdomyosarcoma Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Rhabdomyosarcoma Drug Market Share Analysis
Rhabdomyosarcoma Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Rhabdomyosarcoma Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Rhabdomyosarcoma Drug sales, revenue and market share for each player covered in this report.
The major players covered in Rhabdomyosarcoma Drug are:
Bellicum Pharmaceuticals Inc
Iproteos SL
Celgene Corp
Boehringer Ingelheim GmbH
Exelixis Inc
Bristol-Myers Squibb Co
MacroGenics Inc
Epizyme Inc
Eisai Co Ltd
Ipsen SA
Taiho Pharmaceutical Co Ltd
NantKwest Inc
Taiwan Liposome Company Ltd
Pfizer Inc
Novartis AG
Tarveda Therapeutics Inc
Noxxon Pharma AG
Among other players domestic and global, Rhabdomyosarcoma Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rhabdomyosarcoma Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Rhabdomyosarcoma Drug, with price, sales, revenue and global market share of Rhabdomyosarcoma Drug in 2018 and 2019.
Chapter 3, the Rhabdomyosarcoma Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rhabdomyosarcoma Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Rhabdomyosarcoma Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Rhabdomyosarcoma Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Rhabdomyosarcoma Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Rhabdomyosarcoma Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 ARI-4175
1.2.3 Celyvir
1.2.4 Crizotinib
1.2.5 Enoblituzumab
1.2.6 AT-69
1.2.7 Axitinib
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Rhabdomyosarcoma Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Research Center
1.3.3 Hospital
1.3.4 Clinic
1.3.5 Others
1.4 Overview of Global Rhabdomyosarcoma Drug Market
1.4.1 Global Rhabdomyosarcoma Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bellicum Pharmaceuticals Inc
2.1.1 Bellicum Pharmaceuticals Inc Details
2.1.2 Bellicum Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bellicum Pharmaceuticals Inc SWOT Analysis
2.1.4 Bellicum Pharmaceuticals Inc Product and Services
2.1.5 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Iproteos SL
2.2.1 Iproteos SL Details
2.2.2 Iproteos SL Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Iproteos SL SWOT Analysis
2.2.4 Iproteos SL Product and Services
2.2.5 Iproteos SL Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Celgene Corp
2.3.1 Celgene Corp Details
2.3.2 Celgene Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Celgene Corp SWOT Analysis
2.3.4 Celgene Corp Product and Services
2.3.5 Celgene Corp Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Boehringer Ingelheim GmbH
2.4.1 Boehringer Ingelheim GmbH Details
2.4.2 Boehringer Ingelheim GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Boehringer Ingelheim GmbH SWOT Analysis
2.4.4 Boehringer Ingelheim GmbH Product and Services
2.4.5 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Exelixis Inc
2.5.1 Exelixis Inc Details
2.5.2 Exelixis Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Exelixis Inc SWOT Analysis
2.5.4 Exelixis Inc Product and Services
2.5.5 Exelixis Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bristol-Myers Squibb Co
2.6.1 Bristol-Myers Squibb Co Details
2.6.2 Bristol-Myers Squibb Co Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bristol-Myers Squibb Co SWOT Analysis
2.6.4 Bristol-Myers Squibb Co Product and Services
2.6.5 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 MacroGenics Inc
2.7.1 MacroGenics Inc Details
2.7.2 MacroGenics Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 MacroGenics Inc SWOT Analysis
2.7.4 MacroGenics Inc Product and Services
2.7.5 MacroGenics Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Epizyme Inc
2.8.1 Epizyme Inc Details
2.8.2 Epizyme Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Epizyme Inc SWOT Analysis
2.8.4 Epizyme Inc Product and Services
2.8.5 Epizyme Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Eisai Co Ltd
2.9.1 Eisai Co Ltd Details
2.9.2 Eisai Co Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Eisai Co Ltd SWOT Analysis
2.9.4 Eisai Co Ltd Product and Services
2.9.5 Eisai Co Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Ipsen SA
2.10.1 Ipsen SA Details
2.10.2 Ipsen SA Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Ipsen SA SWOT Analysis
2.10.4 Ipsen SA Product and Services
2.10.5 Ipsen SA Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Taiho Pharmaceutical Co Ltd
2.11.1 Taiho Pharmaceutical Co Ltd Details
2.11.2 Taiho Pharmaceutical Co Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Taiho Pharmaceutical Co Ltd SWOT Analysis
2.11.4 Taiho Pharmaceutical Co Ltd Product and Services
2.11.5 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 NantKwest Inc
2.12.1 NantKwest Inc Details
2.12.2 NantKwest Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 NantKwest Inc SWOT Analysis
2.12.4 NantKwest Inc Product and Services
2.12.5 NantKwest Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Taiwan Liposome Company Ltd
2.13.1 Taiwan Liposome Company Ltd Details
2.13.2 Taiwan Liposome Company Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Taiwan Liposome Company Ltd SWOT Analysis
2.13.4 Taiwan Liposome Company Ltd Product and Services
2.13.5 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Pfizer Inc
2.14.1 Pfizer Inc Details
2.14.2 Pfizer Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Pfizer Inc SWOT Analysis
2.14.4 Pfizer Inc Product and Services
2.14.5 Pfizer Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Novartis AG
2.15.1 Novartis AG Details
2.15.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Novartis AG SWOT Analysis
2.15.4 Novartis AG Product and Services
2.15.5 Novartis AG Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Tarveda Therapeutics Inc
2.16.1 Tarveda Therapeutics Inc Details
2.16.2 Tarveda Therapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Tarveda Therapeutics Inc SWOT Analysis
2.16.4 Tarveda Therapeutics Inc Product and Services
2.16.5 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Noxxon Pharma AG
2.17.1 Noxxon Pharma AG Details
2.17.2 Noxxon Pharma AG Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Noxxon Pharma AG SWOT Analysis
2.17.4 Noxxon Pharma AG Product and Services
2.17.5 Noxxon Pharma AG Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Rhabdomyosarcoma Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Rhabdomyosarcoma Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Rhabdomyosarcoma Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Rhabdomyosarcoma Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Rhabdomyosarcoma Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Rhabdomyosarcoma Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Rhabdomyosarcoma Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
4.3 Europe Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
4.5 South America Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Rhabdomyosarcoma Drug Sales, Revenue and Market Share by Country
5.1.1 North America Rhabdomyosarcoma Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Rhabdomyosarcoma Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
5.3 Canada Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Rhabdomyosarcoma Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Rhabdomyosarcoma Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Rhabdomyosarcoma Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
6.3 UK Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
6.4 France Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
6.5 Russia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
6.6 Italy Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Rhabdomyosarcoma Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Rhabdomyosarcoma Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Rhabdomyosarcoma Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
7.3 Japan Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
7.4 Korea Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
7.5 India Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
7.7 Australia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Rhabdomyosarcoma Drug Sales, Revenue and Market Share by Country
8.1.1 South America Rhabdomyosarcoma Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Rhabdomyosarcoma Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Rhabdomyosarcoma Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Rhabdomyosarcoma Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Rhabdomyosarcoma Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Rhabdomyosarcoma Drug Sales and Market Share by Type (2015-2020)
10.2 Global Rhabdomyosarcoma Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Rhabdomyosarcoma Drug Price by Type (2015-2020)
11 Global Rhabdomyosarcoma Drug Market Segment by Application
11.1 Global Rhabdomyosarcoma Drug Sales Market Share by Application (2015-2020)
11.2 Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2015-2020)
11.3 Global Rhabdomyosarcoma Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Rhabdomyosarcoma Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Rhabdomyosarcoma Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Rhabdomyosarcoma Drug Market Forecast (2021-2025)
12.2.2 Europe Rhabdomyosarcoma Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Rhabdomyosarcoma Drug Market Forecast (2021-2025)
12.2.4 South America Rhabdomyosarcoma Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Rhabdomyosarcoma Drug Market Forecast (2021-2025)
12.3 Rhabdomyosarcoma Drug Market Forecast by Type (2021-2025)
12.3.1 Global Rhabdomyosarcoma Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Rhabdomyosarcoma Drug Market Share Forecast by Type (2021-2025)
12.4 Rhabdomyosarcoma Drug Market Forecast by Application (2021-2025)
12.4.1 Global Rhabdomyosarcoma Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Rhabdomyosarcoma Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Rhabdomyosarcoma Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Rhabdomyosarcoma Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Rhabdomyosarcoma Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Bellicum Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 8. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Major Business
Table 9. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 10. Bellicum Pharmaceuticals Inc SWOT Analysis
Table 11. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product and Services
Table 12. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Iproteos SL Basic Information, Manufacturing Base and Competitors
Table 14. Iproteos SL Rhabdomyosarcoma Drug Major Business
Table 15. Iproteos SL Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 16. Iproteos SL SWOT Analysis
Table 17. Iproteos SL Rhabdomyosarcoma Drug Product and Services
Table 18. Iproteos SL Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Celgene Corp Basic Information, Manufacturing Base and Competitors
Table 20. Celgene Corp Rhabdomyosarcoma Drug Major Business
Table 21. Celgene Corp Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 22. Celgene Corp SWOT Analysis
Table 23. Celgene Corp Rhabdomyosarcoma Drug Product and Services
Table 24. Celgene Corp Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 26. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Major Business
Table 27. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 28. Boehringer Ingelheim GmbH SWOT Analysis
Table 29. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product and Services
Table 30. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Exelixis Inc Basic Information, Manufacturing Base and Competitors
Table 32. Exelixis Inc Rhabdomyosarcoma Drug Major Business
Table 33. Exelixis Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 34. Exelixis Inc SWOT Analysis
Table 35. Exelixis Inc Rhabdomyosarcoma Drug Product and Services
Table 36. Exelixis Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Bristol-Myers Squibb Co Basic Information, Manufacturing Base and Competitors
Table 38. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Major Business
Table 39. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 40. Bristol-Myers Squibb Co SWOT Analysis
Table 41. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product and Services
Table 42. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. MacroGenics Inc Basic Information, Manufacturing Base and Competitors
Table 44. MacroGenics Inc Rhabdomyosarcoma Drug Major Business
Table 45. MacroGenics Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 46. MacroGenics Inc SWOT Analysis
Table 47. MacroGenics Inc Rhabdomyosarcoma Drug Product and Services
Table 48. MacroGenics Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Epizyme Inc Basic Information, Manufacturing Base and Competitors
Table 50. Epizyme Inc Rhabdomyosarcoma Drug Major Business
Table 51. Epizyme Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 52. Epizyme Inc SWOT Analysis
Table 53. Epizyme Inc Rhabdomyosarcoma Drug Product and Services
Table 54. Epizyme Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Eisai Co Ltd Basic Information, Manufacturing Base and Competitors
Table 56. Eisai Co Ltd Rhabdomyosarcoma Drug Major Business
Table 57. Eisai Co Ltd Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 58. Eisai Co Ltd SWOT Analysis
Table 59. Eisai Co Ltd Rhabdomyosarcoma Drug Product and Services
Table 60. Eisai Co Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Ipsen SA Basic Information, Manufacturing Base and Competitors
Table 62. Ipsen SA Rhabdomyosarcoma Drug Major Business
Table 63. Ipsen SA Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 64. Ipsen SA SWOT Analysis
Table 65. Ipsen SA Rhabdomyosarcoma Drug Product and Services
Table 66. Ipsen SA Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Taiho Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table 68. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Major Business
Table 69. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 70. Taiho Pharmaceutical Co Ltd SWOT Analysis
Table 71. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product and Services
Table 72. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. NantKwest Inc Basic Information, Manufacturing Base and Competitors
Table 74. NantKwest Inc Rhabdomyosarcoma Drug Major Business
Table 75. NantKwest Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 76. NantKwest Inc SWOT Analysis
Table 77. NantKwest Inc Rhabdomyosarcoma Drug Product and Services
Table 78. NantKwest Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Taiwan Liposome Company Ltd Basic Information, Manufacturing Base and Competitors
Table 80. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Major Business
Table 81. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 82. Taiwan Liposome Company Ltd SWOT Analysis
Table 83. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product and Services
Table 84. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Inc Rhabdomyosarcoma Drug Major Business
Table 87. Pfizer Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 88. Pfizer Inc SWOT Analysis
Table 89. Pfizer Inc Rhabdomyosarcoma Drug Product and Services
Table 90. Pfizer Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 92. Novartis AG Rhabdomyosarcoma Drug Major Business
Table 93. Novartis AG Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 94. Novartis AG SWOT Analysis
Table 95. Novartis AG Rhabdomyosarcoma Drug Product and Services
Table 96. Novartis AG Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Tarveda Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 98. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Major Business
Table 99. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 100. Tarveda Therapeutics Inc SWOT Analysis
Table 101. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product and Services
Table 102. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. Noxxon Pharma AG Basic Information, Manufacturing Base and Competitors
Table 104. Noxxon Pharma AG Rhabdomyosarcoma Drug Major Business
Table 105. Noxxon Pharma AG Rhabdomyosarcoma Drug Total Revenue (USD Million) (2018-2019)
Table 106. Noxxon Pharma AG SWOT Analysis
Table 107. Noxxon Pharma AG Rhabdomyosarcoma Drug Product and Services
Table 108. Noxxon Pharma AG Rhabdomyosarcoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. Global Rhabdomyosarcoma Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 110. Global Rhabdomyosarcoma Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 111. Global Rhabdomyosarcoma Drug Sales by Regions (2015-2020) (K Pcs)
Table 112. Global Rhabdomyosarcoma Drug Sales Market Share by Regions (2015-2020)
Table 113. Global Rhabdomyosarcoma Drug Revenue by Regions (2015-2020) (USD Million)
Table 114. North America Rhabdomyosarcoma Drug Sales by Countries (2015-2020) (K Pcs)
Table 115. North America Rhabdomyosarcoma Drug Sales Market Share by Countries (2015-2020)
Table 116. North America Rhabdomyosarcoma Drug Revenue by Countries (2015-2020) (USD Million)
Table 117. North America Rhabdomyosarcoma Drug Revenue Market Share by Countries (2015-2020)
Table 118. Europe Rhabdomyosarcoma Drug Sales by Countries (2015-2020) (K Pcs)
Table 119. Europe Rhabdomyosarcoma Drug Sales Market Share by Countries (2015-2020)
Table 120. Europe Rhabdomyosarcoma Drug Revenue by Countries (2015-2020) (USD Million)
Table 121. Asia-Pacific Rhabdomyosarcoma Drug Sales by Regions (2015-2020) (K Pcs)
Table 122. Asia-Pacific Rhabdomyosarcoma Drug Sales Market Share by Regions (2015-2020)
Table 123. Asia-Pacific Rhabdomyosarcoma Drug Revenue by Regions (2015-2020) (USD Million)
Table 124. South America Rhabdomyosarcoma Drug Sales by Countries (2015-2020) (K Pcs)
Table 125. South America Rhabdomyosarcoma Drug Sales Market Share by Countries (2015-2020)
Table 126. South America Rhabdomyosarcoma Drug Revenue by Countries (2015-2020) (USD Million)
Table 127. South America Rhabdomyosarcoma Drug Revenue Market Share by Countries (2015-2020)
Table 128. Middle East & Africa Rhabdomyosarcoma Drug Sales by Countries (2015-2020) (K Pcs)
Table 129. Middle East & Africa Rhabdomyosarcoma Drug Sales Market Share by Countries (2015-2020)
Table 130. Middle East & Africa Rhabdomyosarcoma Drug Revenue by Countries (2015-2020) (USD Million)
Table 131. Middle East & Africa Rhabdomyosarcoma Drug Revenue Market Share by Countries (2015-2020)
Table 132. Global Rhabdomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 133. Global Rhabdomyosarcoma Drug Sales Share by Type (2015-2020)
Table 134. Global Rhabdomyosarcoma Drug Revenue by Type (2015-2020) (USD Million)
Table 135. Global Rhabdomyosarcoma Drug Revenue Share by Type (2015-2020)
Table 136. Global Rhabdomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 137. Global Rhabdomyosarcoma Drug Sales Share by Application (2015-2020)
Table 138. Global Rhabdomyosarcoma Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 139. Global Rhabdomyosarcoma Drug Market Share Forecast by Regions (2021-2025)
Table 140. Global Rhabdomyosarcoma Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 141. Global Rhabdomyosarcoma Drug Market Share Forecast by Type (2021-2025)
Table 142. Global Rhabdomyosarcoma Drug Sales Forecast by Application (2021-2025)
Table 143. Global Rhabdomyosarcoma Drug Market Share Forecast by Application (2021-2025)
Table 144. Direct Channel Pros & Cons
Table 145. Indirect Channel Pros & Cons
Table 146. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Rhabdomyosarcoma Drug Picture
Figure 2. Global Sales Market Share of Rhabdomyosarcoma Drug by Type in 2019
Figure 3. ARI-4175 Picture
Figure 4. Celyvir Picture
Figure 5. Crizotinib Picture
Figure 6. Enoblituzumab Picture
Figure 7. AT-69 Picture
Figure 8. Axitinib Picture
Figure 9. Others Picture
Figure 10. Rhabdomyosarcoma Drug Sales Market Share by Application in 2018
Figure 11. Research Center Picture
Figure 12. Hospital Picture
Figure 13. Clinic Picture
Figure 14. Others Picture
Figure 15. Global Rhabdomyosarcoma Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 16. United States Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Canada Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Mexico Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Germany Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. France Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. UK Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Russia Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Italy Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. China Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Japan Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Korea Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. India Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Southeast Asia Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Australia Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 30. Brazil Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Egypt Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Saudi Arabia Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. South Africa Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Turkey Rhabdomyosarcoma Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 35. Global Rhabdomyosarcoma Drug Sales Market Share by Manufacturer in 2019
Figure 36. Global Rhabdomyosarcoma Drug Revenue Market Share by Manufacturer in 2019
Figure 37. Top 3 Rhabdomyosarcoma Drug Manufacturer (Revenue) Market Share in 2019
Figure 38. Top 6 Rhabdomyosarcoma Drug Manufacturer (Revenue) Market Share in 2019
Figure 39. Key Manufacturer Market Share Trend
Figure 40. Global Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 41. Global Rhabdomyosarcoma Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 42. Global Rhabdomyosarcoma Drug Revenue Market Share by Regions (2015-2020)
Figure 43. Global Rhabdomyosarcoma Drug Revenue Market Share by Regions in 2018
Figure 44. North America Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
Figure 45. Europe Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
Figure 47. South America Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
Figure 48. Middle East & Africa Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020)
Figure 49. North America Rhabdomyosarcoma Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 50. North America Rhabdomyosarcoma Drug Sales Market Share by Countries (2015-2020)
Figure 51. North America Rhabdomyosarcoma Drug Sales Market Share by Countries in 2018
Figure 52. North America Rhabdomyosarcoma Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 53. North America Rhabdomyosarcoma Drug Revenue Market Share by Countries in 2018
Figure 54. United States Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Canada Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. Mexico Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. Europe Rhabdomyosarcoma Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 58. Europe Rhabdomyosarcoma Drug Revenue Market Share by Countries (2015-2020)
Figure 59. Europe Rhabdomyosarcoma Drug Revenue Market Share by Countries in 2019
Figure 60. Germany Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. UK Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. France Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Russia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Italy Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Asia-Pacific Rhabdomyosarcoma Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 66. Asia-Pacific Rhabdomyosarcoma Drug Sales Market Share by Regions 2019
Figure 67. Asia-Pacific Rhabdomyosarcoma Drug Revenue Market Share by Regions 2019
Figure 68. China Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. Japan Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Korea Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. India Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Southeast Asia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. South America Rhabdomyosarcoma Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. South America Rhabdomyosarcoma Drug Sales Market Share by Countries in 2019
Figure 75. South America Rhabdomyosarcoma Drug Revenue Market Share by Countries in 2019
Figure 76. Brazil Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 77. Argentina Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 78. Middle East and Africa Rhabdomyosarcoma Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 79. Middle East and Africa Rhabdomyosarcoma Drug Sales Market Share by Countries in 2019
Figure 80. Middle East and Africa Rhabdomyosarcoma Drug Revenue Market Share by Countries (2015-2020)
Figure 81. Middle East and Africa Rhabdomyosarcoma Drug Revenue Market Share by Countries in 2019
Figure 82. Saudi Arabia Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. Egypt Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Turkey Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 85. South Africa Rhabdomyosarcoma Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 86. Global Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 87. Global Rhabdomyosarcoma Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 88. North America Sales Rhabdomyosarcoma Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. Europe Sales Rhabdomyosarcoma Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. Asia-Pacific Sales Rhabdomyosarcoma Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. South America Sales Rhabdomyosarcoma Drug Market Forecast (2021-2025) (K Pcs)
Figure 92. Middle East & Africa Sales Rhabdomyosarcoma Drug Market Forecast (2021-2025) (K Pcs)
Figure 93. Sales Channel: Direct Channel vs Indirect Channel
甲状腺機能低下症治療の世界市場 2020年 Market Overview The global Hypothyroidism Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Hypothyroidism Drug marke…- 小売用医薬品の世界市場 2020年 Market Overview The global Retail Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.8% in the forecast period of 2020 to 2025 and will expected to reach USD 1350.1 million by 2025, from USD 1211 million in 2019. The Retail Drug market report …
- シャルコー・マリー・トゥース病I型治療薬の世界市場 2020年 Market Overview The global Charcot-Marie-Tooth Disease Type I A Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cha…
- アンカ血管炎薬の世界市場 2020年 Market Overview The global Anca Vasculitis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anca Vasculitis Drug mar…
- 退形成性オリゴ星細胞腫薬の世界市場 2020年 Market Overview The global Anaplastic Oligoastrocytoma Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anaplastic O…